Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Wednesday 15 January, 2003

Xenova Group PLC

ImmuLogic Interests

Xenova Group PLC
15 January 2003

                                Xenova Group plc

                          Addiction Treatment Vaccines
                 Xenova Buyout of Residual ImmuLogic Interests

Slough, UK, January 15, 2003  -  Xenova Group plc (NASDAQ NM: XNVA; London Stock
Exchange: XEN) today announces that it has reached an agreement with ImmuLogic
Pharmaceutical Corporation Liquidating Trust ('ImmuLogic') under which Xenova
will buy out all remaining ImmuLogic rights to future milestone and royalty
payments relating to two of Xenova's development stage vaccine programmes, TA-CD
and TA-NIC.

Under the terms of the agreement announced today, ImmuLogic will receive US$1m
from Xenova in return for ImmuLogic's rights to all future payments relating to
the two vaccine programmes.  Mutual releases from claims, proceedings and any
other liabilities were also exchanged.

Under a 1998 Purchase Agreement, Cantab Pharmaceuticals plc (which merged with
Xenova in 2001) undertook to pay ImmuLogic certain milestone payments relating
to the TA-CD and TA-NIC programmes, payable at the end of each clinical
development phase and valued at up to $11m, plus royalties.

ImmuLogic began voluntary liquidation proceedings in August 1999 and is now
expected to complete its liquidation following a final cash distribution to its
former shareholders.

In order to fund the buyout of ImmuLogic's interests, Xenova has raised £680,000
before expenses through the placing for cash of 1,766,235 new ordinary shares of
10 pence each.  The new shares, which represent approximately 1.02 per cent of
the Company's issued share capital prior to the placing, have been placed by
Nomura International plc at a price of 38.5 pence per share.  The placing
represents a discount of approximately 9.9 per cent to the closing middle market
price on the London Stock Exchange on 14 January 2003.

Application will be made today for the 1,766,235 new shares to be admitted to
the Official List and to trading on the London Stock Exchange, with admission
expected to become effective on 20 January 2003.  When issued, the new shares
will rank pari passu in all respects with the Company's existing ordinary

Commenting on today's news, David Oxlade, Chief Executive of Xenova, said:

'We are delighted with this agreement, which releases Xenova from large
potential payment obligations and consequently increases our commercial
flexibility in relation to both TA-CD and TA-NIC.  Both programmes have a large
commercial potential and are designed to assist the significant number of people
worldwide who find it difficult to overcome their addiction.'

                                    - ends -

UK:                                                 US:
Xenova Group plc                                    Trout Group/BMC Communications
Tel: +44 (0)1753 706600                             Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer             Press: Brad Miles (Ext 17) Lauren Tortorete (Ext 20)
Daniel Abrams, Group Finance Director               Investors: Jonathan Fassberg (Ext 16) Lee Stern (Ext 22)
Hilary Reid Evans, Corporate Communications

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell

Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova has a broad pipeline of
programmes in clinical development.  The Group has a well-established track
record in the identification, development and partnering of innovative products
and technologies and has partnerships with significant pharmaceutical companies
including Lilly, Pfizer, Celltech, Genentech, QLT and Millennium

TA-NIC, an anti-nicotine vaccine designed to assist in giving up smoking,
successfully completed a Phase I trial in mid-2002.  This was the first
evaluation of an anti-nicotine vaccine in man.  It is anticipated that TA-NIC
will enter a further Phase I trial in mid 2003.

A Phase IIa dose escalation study is currently underway for TA-CD, an
anti-cocaine vaccine.  This study is designed to evaluate the safety and
immunogenicity of a four or five dose vaccination schedule and the results are
expected in the second half of 2003.  A further Phase II 'cocaine
administration' study is expected to begin in early 2003.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialisation of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialise products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialisation activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                                                                             

a d v e r t i s e m e n t